Hypothesis: The skeleton acts as an endocrine regulator of multicellular fidelity, actively suppressing atavistic cancer programs through bone-derived osteocalcin (OCN) and sclerostin. Age-related decline in skeletal endocrine output removes a critical checkpoint that maintains repression of ancient unicellular survival programs, enabling the epigenetic de-repression events described in the atavistic theory.

Mechanistic Framework:

What actively maintains suppression of these ancient programs in healthy tissue? The atavistic theory itself doesn't address this. We believe bone-derived factors fill this systemic regulatory role.

Cancer, according to the atavistic model, represents reversion to phylostrata 1-2 gene expression programs through epigenetic de-repression of TERT, Wnt/β-catenin pathway hijacking, and metabolic reversion to glycolysis. But there's a gap in the literature—what keeps these programs silenced in normal tissue?

Osteocalcin Mechanism: OCN binds to GPR37L1 in neural tissue and regulates p53-Sp1 interactions critical for TERT suppression. Our hypothesis is that OCN enhances p53 transcriptional activity at the TERT promoter while disrupting Sp1-mediated activation, maintaining CTCF complex integrity. When OCN declines with age (roughly 30-50% reduction from ages 30 to 80), this suppression lifts. That's when ETS transcription factors can bind and reactivate TERT—the pattern we see in 85-95% of cancers.

Sclerostin Mechanism: Osteocyte-derived sclerostin inhibits Wnt/β-catenin signaling, a pathway that cancer specifically hijacks to induce TERT and pluripotency genes. We propose sclerostin acts as a systemic Wnt gatekeeper. Its age-related decline allows β-catenin to accumulate and translocate to the nucleus, triggering the canonical atavistic transcriptional program.

Testable Predictions:

1. High-dose OCN administration will suppress TERT expression in cancer cell lines through p53-dependent mechanisms
2. Sclerostin knockout mice will exhibit accelerated tumor formation in Wnt-dependent cancer models
3. Human osteocalcin levels will inversely correlate with telomere length maintenance markers in peripheral blood cells
4. Bone-specific senescence (senolytic accumulation in osteocytes) will precede systemic atavistic marker elevation

This framework reframes cancer—not just as a mutation disease, but as a deficiency of systemic multicellular enforcement. That's something we might actually address through skeletal endocrine modulation.